Targeting lung-resident TNFR2+ cDC2 (R2D2) subpopulation to treat asthma
View Patent ↗Provided herein are compositions and methods for treating an inflammatory respiratory disorder. Exemplified are corn-positions comprising interferon-beta of IFN-beta-fusion peptides.
1 . A method for treating asthma or chronic obstructive pulmonary disease (COPD), comprising administering by pulmonary or intranasal delivery to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of interferon-beta (IFNB) or an IFNB fusion protein, wherein the IFNB or the IFNB fusion protein comprises the sequence of SEQ ID NO: 2 or SEQ ID NO: 3.
2 . The method of claim 1 , wherein the IFNB fusion protein comprises an IFNB-Tumor necrosis factor (TNF) fusion protein.
3 . The method of claim 2 , wherein the IFNB-TNF fusion protein comprises SEQ ID NO: 2 linked to SEQ ID NO: 5, a fragment of SEQ ID NO: 5, or a variant of SEQ ID NO: 5 having at least 90% identity therewith.
4 . The method of claim 2 , wherein the IFNB-TNF fusion protein comprises SEQ ID NO: 2 linked to SEQ ID NO: 5.
5 . The method of claim 1 , wherein the pharmaceutical composition is in a form for inhalation.
6 . The method of claim 1 , wherein the therapeutically effective amount is an amount sufficient to induce lung T regulatory cells.
7 . The method of claim 1 , wherein the pharmaceutical composition is an aerosol.
8 . The method of claim 1 , wherein the method treats asthma.
9 . The method of claim 1 , wherein the pharmaceutical composition further comprises a steroid or methotrexate.
10 . The method of claim 1 , wherein the pharmaceutical composition lacks a neuraminidase inhibitor.
11 . The method of claim 1 , wherein the IFNB fusion protein comprises an anti-TNFR2 non-blocking antibody fused to IFNB.
12 . The method of claim 1 , wherein the IFNB fusion protein comprises an anti-Mg12 antibody fused to IFNB.